Dyslipidemia in systemic lupus erythematosus: Just another comorbidity?

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 5, 2016, Pages 604-610

  Tselios, Konstantinos ^a   Koumaras, Charalambos ^b   Gladman, Dafna D ^a   Urowitz, Murray B ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b 424 General Army Hospital   (Greece)

Author keywords

Dyslipidemia; Pathogenesis; Systemic lupus erythematosus; Therapy

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; CXCL9 CHEMOKINE; CYCLOSPORIN A; EVEROLIMUS; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; RAPAMYCIN; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; BIOACCUMULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE COURSE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; HUMAN; HYPERTRIGLYCERIDEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OXIDATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; DYSLIPIDEMIAS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS;

COMORBIDITY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREVALENCE; PROGNOSIS;

EID: 84961577209     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.10.010     Document Type: Article

References (116)

1. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
2. Mok C.C., Kwok C.L., Ho L.Y., Chan P.T., Yip S.F. Life expectancy, standardized mortality ratios and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011, 63:1182-1189.
3. Wade N.S., Major A.S. The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. Thromb Haemost 2011, 106:849-857.
4. Skaggs B.J., Hahn B.H., McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012, 8:214-223.
5. Reich H.N., Gladman D.D., Urowitz M.B., Bargman J.M., Hladunewich M.A., Lou W., et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int 2011, 79:914-920.
6. Tisseverasinghe A., Lim S., Greenwood C., Urowitz M.B., Gladman D., Fortin P.R. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2211-2219.
7. Merayo-Chalico J., Apodaca E., Barrera-Vargas A., Alcocer-Varela J., Colunga-Pedraza I., Gonzalez-Patino A., et al. Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry 2015, [pii: jnnp-2014-310145].
8. Piga M., Peltz M.T., Montaldo C., Perra D., Sanna G., Cauli A., et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev 2015, 14:510-516.
9. Urowitz M.B., Gladman D.D., Ibanez D., Fortin P., Sanchez-Guerrero J., Bae A., et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007, 16:731-735.
10. Urowitz M.B., Gladman D.D., Ibanez D., Fortin P., Sanchez-Guerrero J., Bae S., et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum 2008, 59:176-180.
11. Toloza S.M., Uribe A.G., McGwin G., Alarcon G.S., Fessler B.J., Bastian H.M., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957.
12. Cardoso C.R., Signorelli F.V., Papi J.A., Salles G.F. Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol Int 2008, 28:323-327.
13. Wijaya L.K., Kasjmir Y.I., Sukmana N., Subekti I., Prihartono J. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones 2005, 37:132-144.
14. Siripaitoon B., Osiri M., Vongthavaravat V., Akkasilpa S., Deesomchok U. The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. Lupus 2004, 13:961-968.
15. Telles R., Lanna C., Ferreira G., Ribeiro A. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010, 19:803-809.
16. Chong Y.B., Yap D.Y., Tang C.S., Chan T.M. Dyslipidaemia in patients with lupus nephritis. Nephrology 2011, 16:511-517.
17. Lagogianni I., Papapanagiotou A., Piperi C., Kalofoutis C., Troupis G., Zachari A., et al. Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clin Biochem 2005, 38:286-290.
18. Tyrrell P.N., Beyene J., Benseler S.M., Sarkissian T., Silverman E.D. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol 2007, 34:2112-2119.
19. Song L.J., Liu W.W., Fan Y.C., Qiu F., Chen Q.L., Li X.F., et al. The positive correlations of apolipoprotein E with disease activity and related cytokines in systemic lupus erythematosus. Diagn Pathol 2013, 8:175.
20. Lahita R.G., Rivkin E., Cavanagh I., Romano P. Low levels of total cholesterol, high-density lipoprotein and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993, 36:1566-1574.
21. Dinu A.R., Merrill J.T., Shen C., Antonov, Myones B.L., Lahita R.G. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998, 7:355-360.
22. Hyka N., Dayer J.M., Modoux C., Kohno T., Edwards C.K., Roux-Lombard P., et al. Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97:2381-2389.
23. Svenungsson E., Engelbertsen D., Wigren M., Gustafsson J.T., Gunarsson I., Elvin K., et al. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clin Exp Immunol 2015, 181:417-426.
24. Kiani A.N., Fang H., Akhter E., Quiroga C., Simpson N., Alaupovic P., et al. Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus. Arthritis Care Res 2015, 67:442-446.
25. Borba E.F., Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolipin antibodies. Lupus 1997, 6:533-539.
26. Olusi S.O., George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc Health Risk Manag 2011, 7:75-80.
27. Hua X., Su J., Svenungsson E., Hurt-Camejo E., Jensen-Urstad K., Angelin B., et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 2009, 38:184-189.
28. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693-707.
29. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.A., Maranhao R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1033-1040.
30. De Carvalho J.F., Bonfa E., Borba E.F. Systemic lupus erythematosus and lupus dyslipoproteinemia. Autoimmun Rev 2008, 7:246-250.
31. De Carvalho J.F., Borba E.F., Viana V.S., Bueno C., Leon E.P., Bonfa E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 2004, 50:3610-3615.
32. Reichlin M., Fesmire J., Quintero-Del-Rio A.I., Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2957-2963.
33. Huang C.S., Wu W.F. Systemic lupus erythematosus associated with extreme hypertriglyceridemia. Pediatr Neonatol 2008, 49:35-38.
34. Ohmura H., Mokuno H., Sawano M., Hatsumi C., Mitsugi Y., Watanabe Y., et al. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism 2002, 51:1081-1087.
35. Frostegard J., Svenungsson E., Wu R., Gunarsson I., Lundberg I.E., Klareskog L., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005, 52:192-200.
36. Van Lenten B.J., Hama S.Y., De Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell co-cultures. J Clin Invest 1995, 96:2758-2767.
37. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993-1007.
38. McMahon M., Grossman J., Skaggs B., Fitzgerald J., Sahakian L., Ragavendra N., et al. Dysfunctional proinflammatory high-density lipoprotein confers increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2428-2437.
39. Van Leeuwen M., Damoiseaux J., Duijvestin A., Cohen Tervaert J.W. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 2009, 9:53-57.
40. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993, 341:923-925.
41. Delgado Alves J., Kumar S., Isenberg D.A. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2003, 42:893-899.
42. Just S.A., Nybo M., Laustrup H., Hansen I.J., Junker P., Vinholt P.J. Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. Lupus 2015, [pii: 0961203315604040].
43. Lopez L.R., Simpson D.F., Hurley B.L., Matsuura E. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 2005, 1051:313-322.
44. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., Hurley B.L., Matsuura E., Garcia-De La Torre I. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006, 15:80-86.
45. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., Gutterman J.U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988, 6:1328-1334.
46. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985, 161:984-995.
47. Svenungsson E., Gunnarsson I., Fei G.Z., Lundberg I.E., Klareskog L., Frostegård J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2533-2540.
48. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006, 33:539-545.
49. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
50. Devaraj S., Singh U., Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009, 20:182-189.
51. Calan M., Calan O., Gonen M.S., Bilgir F., Kebapcilar L., Kulac E., et al. Examination of adhesion molecules, homocysteine and hs-CRP in patients with polygenic hypercholesterolemia and isolated hypertriglyceridemia. Intern Med 2011, 50:1529-1535.
52. Nikpour M., Harvey P., Ibanez D., Gladman D.D., Urowitz M.B. High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis Rheum 2012, 64:3052-3053.
53. Formiga F., Meco J.F., Pinto X., Jacob J., Moga I., Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001, 10:359-363.
54. Arnaldi G., Scandali V.M., Trementino L., Cardinaletti M., Appolloni G., Boscaro M. Pathophysiology of dyslipidemia in Cushing[U+05F3]s syndrome. Neuroendocrinology 2010, 92(Suppl 1):86-90.
55. Cairoli E., Rebella M., Danese N., Garra V., Borba E.F. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012, 21:1178-1182.
56. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., Bruce I.N. The cholesterol lowering effect of anti-malarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325-330.
57. Tam L.S., Gladman D.D., Hallett D.C., Rahman P., Urowitz M.B. Effect of anti-malarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000, 27:2142-2145.
58. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl 1):S16-S22.
59. Germano V., Picchianti Diamanti A., Ferlito C., Podesta E., Salemi S., Migliore A., et al. Cyclosporine A in the long term management of systemic lupus erythematosus. J Biol Regul Homeost Agents 2011, 25:397-403.
60. Yap D.H., Ma M.K., Tang C.S., Chan T.M. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology 2012, 17:676-680.
61. Sazliyana S., Mosd Sahrir M.S., Kong C.T., Tan H.J., Hamidon B.B., Azmi M.T. Implications of immunosuppressive agents in cardiovascular risk and carotid intima media thickness among lupus nephritis patients. Lupus 2011, 20:1260-1266.
62. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997, 145:408-415.
63. Ballocca F., D'Ascenzo F., Moretti C., Omede P., Cerrato E., Barbero U., et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prevent Cardiol 2014, [pii: 2047487314546826].
64. Nikpour M., Urowitz M.B., Ibanez D., Harvey P., Gladman D.D. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther 2011, 13:R156.
65. Rahman P., Aguero S., Gladman D.D., Hallett D., Urowitz M.B. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000, 9:672-675.
66. Touma Z., Gladman D.D., Ibanez D., Urowitz M.B. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology 2012, 51:528-534.
67. Bhatt S.P., Handa R., Gulati G.S., Sharma S., Pandey R.M., Aggarwal P., et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006, 35:128-132.
68. Boucelma M., Haddoum F., Chaudet H., Kaplanski G., Mazouni-Brahimi N., Reziq-Ladjouze A., et al. Cardiovascular risk and lupus disease. Int Angiol 2011, 30:18-24.
69. Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Pratt J.E., Tracy R.P., Kuller L.H., et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004, 50:151-159.
70. Kiani A.N., Post W.S., Magder L.S., Petri M. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology 2011, 50:2071-2079.
71. Kaul M.S., Rao S.V., Shaw L.K., Honeycutt E., Ardoin S.P., Clair E.W. Association of systemic lupus erythematosus with angiographically-defined coronary artery disease: a retrospective cohort study. Arthritis Care Res 2013, 65:266-273.
72. Bruce I.N., Urowitz M.B., Gladman D.D., Hallett D.C. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137-2143.
73. Thompson T., Sutton-Tyrell K., Wildman R.P., Kao A., Fitzgerald S.G., Shook B., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008, 58:835-842.
74. Eder L., Gladman D.D., Ibanez D., Urowitz M.B. The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. Lupus 2014, 23:1142-1148.
75. Wang X.Y., Tang X.Q., Huang Y.J., Chen W.Y., Yu X.Q. Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol 2012, 31:669-675.
76. Cypiene A., Kovaite M., Venalis A., Dadoniene J., Rugiene R., Petrulioniene Z., et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus 2009, 18:522-529.
77. Goldberg R.J., Urowitz M.B., Ibanez D., Nikpour M., Gladman D.D. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009, 36:2454-2461.
78. Parra S., Vives G., Ferre R., Gonzalez M., Guardiola M., Ribalta J., et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis 2012, 225:224-230.
79. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
80. Luzar B., Ferluga D. Role of lipids in the progression of renal disease in systemic lupus erythematosus patients. Wien Klin Wochenschr 2000, 112:716-721.
81. Griffin B., Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus 2013, 22:1267-1273.
82. MaLaurin E.Y., Holliday S.L., Williams P., Brey R.L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297-303.
83. Makol A., Petri M. Pancreatitis in systemic lupus erythematosus: frequency and associated factors-a review of the Hopkins Lupus Cohort. J Rheumatol 2010, 37:341-345.
84. Ferreira G.A., Navarro T.P., Telles R.W., Andrade L.E., Sato E.I. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007, 46:1560-1565.
85. Schanberg L.E., Sandborg C., Barnhart H.X., Ardoin S.P., Yow E., Evans G.W., et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012, 64:285-296.
86. Ardoin S.P., Schanberg L.E., Sandborg C.I., Barnhart H.X., Evans G.W., Yow E., et al. Secondary analysis of the APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal patients with higher C reactive protein. Ann Rheum Dis 2014, 73:557-566.
87. Mok C.C., Wong C.K., To C.H., Lai J.P., Lam C.S. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011, 63:875-883.
88. De Kruif M.D., Limper M., Hansen H.R., De Ruiter J., Spek C.A., Van Gorp E.C., et al. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68:1654.
89. Plazak W., Gryga K., Dziedzic H., Tomkiewicz-Pajak L., Konieczynska M., Podolec P., et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011, 13:R117.
90. Petri M.A., Kiani A.N., Post W., Christopher-Stine L., Magder L.S. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011, 70:760-765.
91. Costenbader K.H., Liang M.H., Chibnik L.B., Aizer J., Kwon H., Gall V., et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007, 27:1071-1077.
92. Norby G.E., Holme I., Fellstrom B., Jardine A., Cole E., Abedini S., et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 2009, 60:1060-1064.
93. Willis R., Seif A.M., McGwin G., Martinez-Martinez L.A., Gonzalez E.B., Doan E., et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort. Clin Exp Rheumatol 2014, 32:162-167.
94. Ye Y., Zhao X., Xie H., Tian Z., Zhang S. Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus. A meta-analysis of randomized controlled trials. Int J Cardiol 2013, 167:301-303.
95. Costenbader K.H., Karlson E.W., Gall V., De Pablo P., Finkch A., Lynch M., et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum 2005, 53:718-723.
96. Anderson T., Gregoire J., Hegele R.A., Couture P., Mancini J., McPherson R., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
97. Perk J., De Backer G., Gohike H., Graham I., Reiner Z., Verschuren M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2012, 33:1635-1701.
98. Chung C.P., Oeser A., Avalos I., Raggi P., Stein C.M. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006, 15:562-569.
99. Urowitz M.B., Ibanez D., Gladman D.D. Adjusted Framingham risk factor scoring for systemic lupus erythematosus. Arthritis Rheum 2011, 1. [abstract].
100. De Leeuw K., Freire B., Smit A.J., Bootsma A.H., Kallenberg C.G., Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006, 15:675-682.
101. Soubrier M., Mathieu S., Hermet M., Makarawiez C., Bruckert E. Do all lupus patients need statins?. Joint Bone Spine 2013, 80:244-249.
102. Ardoin S.P., Sandborg C., Schanberg L.E. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007, 16:618-626.
103. Van Leuven S.I., Mendez-Fernandez Y.V., Stroes E.S., Tak P.P., Major A.S. Statin therapy in lupus-mediated atherogenesis: two birds with one-stone?. Ann Rheum Dis 2011, 70:245-248.
104. Woo J.M., Lin Z., Navab M., Van Dyck C., Trejo-Lopez Y., Woo K.M., et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine model of accelerated atherosclerosis. Arthritis Res Ther 2010, 12:R93.
105. Lawman S., Mauri C., Jury E.C., Cook H.T., Ehrenstein M.R. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004, 173:7641-7646.
106. Graham K.L., Lee L.Y., Higgins J.P., Steinman L., Utz P.J., Ho P.P. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 2008, 58:2098-2104.
107. Aprahamian T., Bonegio R., Rizzo J., Perlman H., Lefer D.J., Rifkin I.R., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006, 177:3028-3034.
108. Jury E.C., Isenberg D.A., Mauri C., Ehrenstein M.R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 2006, 177:7416-7422.
109. Amuro H., Ito T., Miyamoto R., Sugimoto H., Torii Y., Son Y., et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010, 62:2073-2085.
110. Ferreira G.A., Teixeira A.L., Sato E.I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 2010, 19:927-934.
111. Tu H., Li Q., Xiang S., Jiang H., Mao Y., Shou Z., et al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role of regulatory T cells. Atherosclerosis 2012, 222:29-33.
112. Noel B. Statins and lupus erythematosus. Rheumatology 2004, 43:397-398.
113. John S.G., Thorn J., Sobonya R. Statins as a potential risk factor for autoimmune diseases: a case report and review. Am J Ther 2013, [Epub ahead of print].
114. Moulis G., Bene J., Sommet A., Sailler L., Lapeyre-Mestre M., Montastruc J.L. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21:885-889.
115. De Jong H.J., Tervaert J.W., Saldi S.R., Vandebriel R.J., Souverein P.C., Meyboom R.H., et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011, 41:373-381.
116. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007, 21:17-24.